Programme :
Presentations by Room
Conference Hall Track 2
Tuesday, 23 February 2021
| TBC | |||||
|
Tue23 Feb11:15am(15 mins)
|
|
Holm Uhlig | |||
|
Room: Conference Hall Track 2
|
|||||
| Bench to bedside Treg therapy development and delivery | |||||
|
Tue23 Feb11:35am(20 mins)
|
|
Dr Ye Htun Oo | |||
|
Room: Conference Hall Track 2
|
|||||
|
Tue23 Feb11:55am(5 mins)
|
Nexcelom Bioscience Ltd |
| type 17 immunity and arthritis | |||||
|
Tue23 Feb12:05pm(20 mins)
|
|
Dr Hussein Al-Mossawi | |||
|
Room: Conference Hall Track 2
|
|||||
|
Tue23 Feb12:45pm(30 mins)
|
Promega UK Ltd Platinum Sponsors |
| Hepcidin and iron-mediated regulation of immunity | |||||
|
Tue23 Feb02:15pm(20 mins)
|
|
Prof Hal Drakesmith | |||
|
Room: Conference Hall Track 2
|
|||||
|
Tue23 Feb02:35pm(15 mins)
|
Merck Presenter: Alex Ko - Global SMC™ Product Manager - EMD Millipore Corp., USA - alex.ko@milliporesigma.com Title: Characterization of SARS-CoV-2 RBD IgG humoral response using Single Molecule Counting (SMC™) technology Abstract: Immunoassay-based serology techniques play key roles in many SARS-CoV-2 research programs due to their ability to identify and characterize the immune response of individuals already infected by the virus through analysis of biomarkers such as immunoglobulins (Ig). However, the limited sensitivity and resolution offered by traditional assay platforms and their serology assays can leave unanswered crucial research questions. We harnessed the power of the Single Molecule Counting (SMC™) ultrasensitive immunoassay platform for the development of new products to address the scientific community’s needs including identifying low level SARS-CoV-2 mediated antibody response and resolving subtle differences in humoral immunity among individuals. The new SMC™ SARS-CoV-2 RBD IgG kit can be used by researchers to accurately understand the extent of SARS-CoV-2 infection in society, thoroughly profile immune responses after vaccine challenge, and understand heterogeneous responses to infection among individuals and subpopulations.’ |
| Trained immunity in diabetes: new targets beyond glucose in diabetes spectrum diseases | |||||
|
Tue23 Feb02:50pm(20 mins)
|
|
Prof Robin Choudhury | |||
|
Room: Conference Hall Track 2
|
|||||
| Lactate: Fuelling the Fire Starter | |||||
|
Tue23 Feb03:15pm(20 mins)
|
|
Dr Claudio Mauro | |||
|
Room: Conference Hall Track 2
|
|||||
Wednesday, 24 February 2021
| Mining the gut microbiome for novel antimicrobial pharmbiotics based on bacteriocins and phage | |||||
|
Wed24 Feb10:55am(15 mins)
|
|
Prof Paul Ross | |||
|
Room: Conference Hall Track 2
|
|||||
|
Wed24 Feb11:15am(15 mins)
|
Promega UK Ltd |
| Translating precision in microbiome science into transformative medicines and biomarkers | |||||
|
Wed24 Feb11:30am(20 mins)
|
|
Dr Anne Neville | |||
|
Room: Conference Hall Track 2
|
|||||
| Gut dysbiosis and response to cancer immunotherapy: from disease phenotyping to therapeutic targeting. | |||||
|
Wed24 Feb11:55am(20 mins)
|
|
Dr David Pinato | |||
|
Room: Conference Hall Track 2
|
|||||
|
Wed24 Feb12:35pm(5 mins)
|
Nexcelom Bioscience Ltd |
|
Wed24 Feb12:40pm(15 mins)
|
Luminex Title - Luminex Flow cytometry and protein analysis tools for Drug Discovery research Presenter - Prabhjoat Chana, Field Application Scientist Luminex Corporation |
| Application of human genetics to improve causality in relationships between the gut microbiome and human disease | |||||
|
Wed24 Feb02:05pm(20 mins)
|
|
Dr Kaitlin Wade | |||
|
Room: Conference Hall Track 2
|
|||||
| Novel Immunotherapeutics to target Gram-negative bacterial infections | |||||
|
Wed24 Feb02:25pm(20 mins)
|
|
Mike Westby | |||
|
Room: Conference Hall Track 2
|
|||||
| Development of oligonucleotide antimicrobials to counter emerging infections | |||||
|
Wed24 Feb02:50pm(20 mins)
|
|
Christian Grøndahl | |||
|
Room: Conference Hall Track 2
|
|||||
| Machine Learning Guided Design of Novel Mode of Action Gram-negative Antibiotics | |||||
|
Wed24 Feb03:10pm(15 mins)
|
|
Paul Finn | |||
|
Room: Conference Hall Track 2
|
|||||
Programme
Hosted By
ELRIG
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
going to the appstore or google play and search for 'elrig'
